Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732860 | 1.00 | PTGS2 (0.62) | PTGS2PTGS1MAPK14 | |
| SCHEMBL6000535 | 0.91 | PTGS2 (0.63) | PTGS2PTGS1 | |
| SCHEMBL5761173 | 0.90 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL7504997 | 0.90 | PTGS2 (0.63) | PTGS2PTGS1MAPK14 | |
| SCHEMBL9029716 | 0.85 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL7503544 | 0.82 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL5089153 | 0.82 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL7506102 | 0.81 | NR4A2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL6002469 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL5823861 | 0.80 | PTGS2 (0.50) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | claimed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | claimed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| US-20060251689-A1 | Treatment or prevention of pruritus | ASTION DEVELOPMENT A/S | 2006-11-09 | — | — | US | disclosed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
| WO-2006102899-A2 | OXAPROZIN OR CLOSELY RELATED COMPOUND FOR THE TREATMENT AND PREVENTION OF | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102898-A2 | OXAPROZIN OR A CLOSELY RELATED COMPOUND FOR THE TREATMENT OF ECZEMA | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102900-A1 | DERMATOLOGICAL COMPOSITIONS AND SALTS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | ASTION PHARMA A/S (DK) | 2006-10-05 | — | — | WO | disclosed |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ASTION DEVELOPMENT A/S | 2006-10-05 | — | — | US | disclosed |
| EP-1707200-A1 | Dermatological compositions comprising oxaprozin or a closely related compound for the treatment of dermatological diseases | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707199-A1 | Oxaprozin or closely related compound for the treatment and prevention of pruritus | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| EP-1707201-A1 | Oxaprozin or a closely related compound for the treatment of eczema | Astion Development A/S (DK) | 2006-10-04 | — | — | EP | disclosed |
| US-5380738-A | Side effect reduction | MONSANTO COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | PTGS2 792/4885PTGS1 745/4885MAPK14 92/4885 |
| US-20060251689-A1 | Treatment or prevention of pruritus | ITCH, TSLP, HRH4 | PTGS2 169/4885PTGS1 131/4885MAPK14 850/4885 |
| US-20060222671-A1 | Dermatological compositions and salts for the treatment of dermatological diseases | ZAP70, SYK, LCK | PTGS2 1589/4885PTGS1 1534/4885MAPK14 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.